Race Oncology appoints chief medical officer

Latest News

Race Oncology (ASX:RAC) has announced the appointment of Dr David Fuller as its chief medical officer (CMO).

Race Oncology is a precision oncology company with an investigational cancer drug called Bisantrene. Bisantrene is a potent inhibitor of the fat mass and obesity-associated (FTO) protein.

The company said Dr Fuller, an internationally experienced biopharmaceutical executive and physician, brings a deep understanding of the successful development and commercialisation of novel pharmaceuticals.

It said his 30 years of R&D experience spans large, mid and small-cap companies including pre-clinical and clinical development, medical and regulatory affairs, and commercialisation.

Dr Fuller will join Race Oncology on 1 July 2021 from Syneos Health Clinical Solutions, where he has been the senior vice president of Clinical Development in the Oncology Business Unit. Dr Fuller also currently serves as cChairman for EpiAxis Therapeutics, a privately owned epigenetic therapeutic and diagnostic company, and is a non-executive director of the ASX-listed biotech company, AdAlta (ASX: 1AD).

Dr Fuller was formerly a director at Linear Clinical Research, chairman of Dimerix Bioscience, CMO/COO at Trident Clinical Research, CMO at Arana Therapeutics and vice-president Clinical at Genzyme Europe.

Commenting on the new appointment, Race Oncology CEO and managing director Phil Lynch said, “This is an important appointment for Race as David brings significant experience and capability. David has been successful in developing a number of pharmaceutical products across various international markets and we look forward to his future guidance in optimising plans for the execution of our Three Pillar strategy and maximising the significant opportunities we have ahead for Bisantrene.”

Dr Fuller said, “I am honoured and excited to be joining Race at such a critical time in the Company’s evolution given the huge potential of Bisantrene as both a targeted precision oncology drug and a differentiated chemotherapeutic. I look forward to applying my experience and expertise to help Race successfully realise the objectives of its three-pillar strategy. And I am pleased to have a new opportunity to again work with Professor Borje Anderson after our successful prior collaboration on Busulfex”.